Matching articles for "Oxytrol"
Issue 1672 · March 20, 2023
Drugs for Overactive Bladder

In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age.…

Med Lett Drugs Ther. 2023 Mar 20; 65(1672):41-5 doi:10.58347/tml.2023.1672a
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Issue 1425 · September 16, 2013 Free
In Brief: Oxytrol OTC

The transdermal patch formulation of the anticholinergic drug oxybutynin ( Oxytrol – Watson) is now available over the counter (OTC) as Oxytrol for Women (MSD) for use in women with overactive bladder (OAB).…

Med Lett Drugs Ther. 2013 Sep 16; 55(1425):76
The transdermal patch formulation of the anticholinergic drug oxybutynin ( Oxytrol – Watson) is now available over the counter (OTC) as Oxytrol for Women (MSD) for use in women with overactive bladder (OAB). It is the first treatment for OAB to become available OTC. Oxybutynin remains available only by prescription for men. OAB, characterized by symptoms of urgency, frequency, and incontinence with no obvious cause, occurs mainly in older women. 1 Behavioral modification, including fluid schedules, timed voiding, pelvic exercises, and urge suppression, is usually tried first. Anticholinergic drugs such as oxybutynin and tolterodine ( Detrol , and others) reduce OAB symptoms by relaxing bladder smooth muscle and inhibiting involuntary detrusor contractions. Dry mouth has been the limiting adverse effect. In clinical studies, the oxybutynin patch was associated with fewer systemic adverse effects, including dry mouth, than the oral drug, but with a high incidence of pruritus at the application site. 2 Oxytrol and Oxytrol for Women both deliver 3.9 mg of oxybutynin per 24 hours and are applied every 4 days, but a box of 8 prescription Oxytrol patches costs $320.32, 3 while an 8-patch box of OTC Oxytrol for Women costs only $29.99. 4 1. EA Gormley et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188:2455. 2. Oxybutynin transdermal (Oxytrol) for overactive bladder. Med Lett Drugs Ther 2003; 45:38. 3. Wholesale acquisition cost (WAC). Source: $ource® Monthly (Selected from FDB MedKnowledge™) September 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail price may be higher. 4. Cost according to drugstore.com. Accessed September 5, 2013. Download complete U.S. English article
Issue 1414 · April 15, 2013
Botox for Overactive Bladder

The FDA has recently approved intradetrusor injection of onabotulinumtoxinA ( Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate or have an inadequate response to…

Med Lett Drugs Ther. 2013 Apr 15; 55(1414):31-2
The FDA has recently approved intradetrusor injection of onabotulinumtoxinA ( Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate or have an inadequate response to anticholinergic therapy. Botox is also approved by the FDA for use in detrusor overactivity associated with a neurologic condition such as multiple sclerosis or spinal cord injury, and for chronic migraine, upper limb spasticity, axillary hyperhidrosis, cervical dystonia, blepharospasm, strabismus, and cosmetic reduction of wrinkles.
Issue 1410 · February 18, 2013
Mirabegron (Myrbetriq) for Overactive Bladder

Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic…

Med Lett Drugs Ther. 2013 Feb 18; 55(1410):13-5
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic agonist to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. OnabotulinumtoxinA (Botox) was also recently approved by the FDA for treatment of overactive bladder and will be reviewed in a future issue.
Issue 1331 · February 8, 2010
Topical Oxybutynin (Gelnique) for Overactive Bladder

The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride ( Gelnique - Watson) for treatment of overactive bladder. Oxybutynin is also…

Med Lett Drugs Ther. 2010 Feb 8; 52(1331):10-1
The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride ( Gelnique - Watson) for treatment of overactive bladder. Oxybutynin is also available for this indication as oral tablets, an oral syrup and a transdermal patch.
Issue 1311 · May 4, 2009
Fesoterodine (Toviaz) for Overactive Bladder

The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.

Med Lett Drugs Ther. 2009 May 4; 51(1311):34-5
The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.
Issue 1204 · March 14, 2005
Solifenacin and Darifenacin for Overactive Bladder

Solifenacin succinate ( VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide ( Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):23-4
Solifenacin succinate ( VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide ( Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Issue 1188 · August 2, 2004
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder

Trospium chloride ( Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available…

Med Lett Drugs Ther. 2004 Aug 2; 46(1188):63-4
Trospium chloride ( Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Issue 1156 · May 12, 2003
Oxybutynin Transdermal (Oxytrol) for Overactive Bladder

A patch formulation of oxybutynin ( Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry mouth.

Med Lett Drugs Ther. 2003 May 12; 45(1156):38-9
A patch formulation of oxybutynin ( Oxytrol - Watson) is now available for treatment of overactive bladder. It is claimed to be as effective as the oral drug, with less dry mouth.